In summary, through data analysis, imaging and functional assays in in vitro and in vivo preclinical models, we demonstrated the anti-cancer effects and feasibility of selectively targeting BMP2/4 in SMAD4 negative EAC by novel anti BMP4 and BMP2/4 VHHs. This evidence concerns the gene BMP2 and cancer.